Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer

Colorectal Cancer Clinical Trial

— 00-046  

Official title:

Colonoscopy Screening Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00102011
• Other study ID #: 00-046
• Secondary ID: MSKCC-00046AUMN-
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: May 2000
• Est. completion date: May 2025

Study information

• Verified date: June 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Screening tests, such as colonoscopy and fecal occult blood test, may help doctors find tumor cells early and plan better treatment for colorectal cancer.

PURPOSE: This randomized phase III trial is studying colonoscopy to see how well it works compared to fecal occult blood test in screening healthy participants for colorectal cancer.

Description:

OBJECTIVES:

• Compare the neoplastic outcome of participants at average risk for colorectal cancer who undergo colonoscopy vs annual fecal occult blood tests.

• Compare the endoscopic and clinical resources required for these screening methods in these participants.

• Compare the benefit-to-harm ratio in participants undergoing these screening methods.

• Determine the level of participation of participants undergoing these screening methods.

OUTLINE: This is a randomized, two-part, multicenter study.

Participants are asked whether they are interested in participating in a randomized controlled trial of colorectal cancer screening.

• Screening colonoscopy feasibility study I (accrual completed as of 12/14/2004):

Participants who are interested in participating in a screening trial are randomized to 1 of 2 screening arms.

• Arm I: Participants undergo baseline screening colonoscopy.

• Arm II: Participants receive standard care.

• Screening colonoscopy feasibility study II: Participants who are interested in participating in a screening trial are randomized to 1 of 2 screening arms.

• Arm I: Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.

• Arm II: Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.

All participants are followed annually for up to 4 years.

PROJECTED ACCRUAL: A total of 1,402 participants (701 per screening arm) have been accrued for feasibility study I within 3 years (accrual completed as of 12/14/2004). An additional 3,550 participants (1,775 per screening arm) will be accrued for feasibility study II within 5 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4952
• Est. completion date: May 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 69 Years

Eligibility

DISEASE CHARACTERISTICS:

• Healthy participants at average risk for developing colorectal cancer

• No history of colorectal cancer

• No history of familial adenomatous polyposis

• More than 5 years since prior flexible sigmoidoscopy

• No prior colonoscopy

PATIENT CHARACTERISTICS:

Age

• 50 to 69 (40 to 69 at the Louisiana State University participating site)

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Cardiovascular

• No myocardial infarction within the past year

• No congestive heart failure

Pulmonary

• No chronic obstructive pulmonary disease

Gastrointestinal

• No history of ulcerative colitis

• No history of Crohn's disease

• No history of inflammatory bowel disease

Other

• No serious comorbid condition

• No consumption of red meat within 3 days prior to and during FOBT (feasibility study II, arm II only)

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No concurrent chemotherapy other than for nonmelanoma skin cancer

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• No vitamin C consumption > 250 mg within 3 days prior to and during fecal occult blood testing (FOBT) (feasibility study II arm II only)

• No nonsteroidal anti-inflammatory drugs within 7 days prior to and during FOBT (feasibility study II, arm II only)

• No concurrent anticoagulants

• No concurrent anticancer therapy except for treatment of nonmelanoma skin cancer

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Procedure:
• annual screening
Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
• fecal occult blood test
Participants undergo a baseline fecal occult blood test (FOBT)
• screening colonoscopy
Patients undergo baseline screening colonoscopy
• standard follow-up care
Standard care

Locations

Country	Name	City	State
United States	Masonic Cancer Center at University of Minnesota (Data collection only)	Minneapolis	Minnesota
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	Kaiser Permanente Washington Health Research Institute (Data collection only)	Seattle	Washington
United States	Feist-Weiller Cancer Center at Louisiana State University Health Sciences	Shreveport	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG. Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study. Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15. No abstract available. — View Citation

Shaukat A, Church TR, Shanley R, Kauff ND, O'Brien MJ, Mills GM, Jordan PA, Allen JA, Kim A, Feld AD, Zauber AG, Winawer SJ. Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy. Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):913-20. doi: 10.1158/1055-9965.EPI-14-1321. Epub 2015 Mar 23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neoplastic findings as assessed by screening colonoscopy vs annual fecal occult blood test (FOBT)-directed colonoscopy		5 years
Primary	Burden on endoscopic and clinical resources		5 years
Primary	Harms associated with screening colonoscopy vs annual FOBT-directed colonoscopy		5 years
Primary	Benefit-to-harm ration for screening colonoscopy vs annual FOBT-directed colonoscopy		5 years
Primary	Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy		5 years

External Links

•   Memorial Sloan Kettering Cancer Center